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Diffuse alveolar hemorrhage (DAH) is a serious pulmonary complication in patients with autoimmune diseases
who are undergoing chemotherapy or have had hematopoietic stem cell transplantation. The use of recombinant
factor VIIa (rFVIIa) to treat the acute phase of DAH by endobronchial bronchoscopy has been shown to have a
significant clinical impact on the survival and evolution of these patients. We report a clinical case of a patient
with DAH secondary to systemic lupus erythematosus (SLE) who was treated with rFVIIa administered using a jet
nebulizer, obtaining an adequate hemostatic effect with immediate control of DAH and a significant improvement
in gas exchange.
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Diffuse alveolar hemorrhage (DAH) is a serious pulmonary
complication secondary to autoimmune diseases, chemo-
therapy, and stem cell transplantation. Its immunopatho-
genesis has been linked to the release of inflammatory
cytokines, which are involved in alveolar capillary endothe-
lial injury and inflammation. Interstitial alveolar inflamma-
tion influences the expression of the intra-alveolar tissue
factor (TF), causing an increase in the markers of thrombin
generation in bronchoalveolar lavage (BAL) fluid [1-5].
Pulmonary complications in systemic lupus erythema-
tosus (SLE) may occur in 50%–70% of patients. Their
clinical spectrum is characterized by pleuritis, interstitial
pneumonitis, thromboembolism (mainly associated with
antiphospholipid syndrome), nodules, bronchiolitis oblit-
erans, infections, diaphragmatic weakness, and DAH.
DAH is a rare manifestation that occurs in 2% to 5.4% of
SLE patient, and it is associated with high mortality,
reaching 50% to 80% [6]. DAH can even occur in patients
treated with steroids and with good disease control. The* Correspondence: teredlt9@hotmail.com
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trolling the immune dysfunction and the inflammatory
process, using steroids, cyclophosphamide, and plasma-
pheresis [6-10].
DAH treatment per se, regardless of its diverse etiology,
includes the use of recombinant activated factor VII
(rFVIIa), administered bronchoscopically or intravenously,
but no information is yet available regarding the use of
this medication inhaled using a jet micronebulizer. The
aim of this paper is to report the case of a female patient
with SLE and DAH who was treated during the active
phase of bleeding with inhaled rFVIIa using a jet
micronebulizer.Case presentation
A 37-year-old female patient with a history of SLE and
Sjögren syndrome was treated with deflazacort 30 mg/day.
The patient was admitted to the hospital with a clinical
picture characterized by abdominal pain, chills, and fever.
Abdominal computed tomography (CT) showed diver-
ticulitis Hinchey III and free fluid in the pelvic cavity, and
the patient underwent laparoscopic surgery, confirmingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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perforation.
Sudden tachycardia, tachypnea, hypoxemia, cough,
and hemoptysis appeared in the immediate postoperative
period, and the patient was transferred to the intensive
care unit (ICU) with respiratory failure and generalized
coarse rales on admission. The cough increased and the
hemoptysis became more evident, reaching approximately
200 mL. The patient had hypoxemia, with 86% oxygen
saturation with 100% FiO2 by pulse oximetry. The blood
gas analysis on admission was as follows: pH 7.18, pCO2
39 mmHg, pO2 42.3 mmHg, lactate 3.3 mmol/L, alveolar-
arterial gradient 455 mmHg, and short circuits 50%.
Hemoglobin decreased from 10 to 7 g/dL. Chest radio-
graphs showed bilateral pulmonary infiltrates occupying
all four quadrants, confirmed by chest CT, on the day of
admission (Figure 1).
Echocardiography showed a dilated right atrium and
ventricle, tricuspid regurgitation, and pulmonary artery
systolic pressure of 42 mmHg. A rheumatic profile
was performed with hypocomplementemia results for
C3 of 21.2 mg/dL (70–152 mg/dL) and C4 of 4.2 mg/dL
(16–38 mg/dL), positive speckled pattern antinuclear
antibodies (ANA) at a titer of 1:1,640, and granular
cytoplasmic fluorescence. Anticentromere antibodies
(antineutrophil cytoplasmic antibody (ANCA)) were
c-ANCA <1:20 (neg <1:20), p-ANCA <1:20 (neg <1:20),
and atypical p-ANCA <1:20 (neg <1:20); erythrocyte sedi-
mentation rate (ESR) was 60 mm/h (0–7.4 mm/h); and
C-reactive protein (CRP) was 71 mg/L (0–20 mg/L).
After the diagnosis of DAH secondary to SLE, treat-
ment was started with rFVIIa at a dose of 50 μg/kg
inhaled with a jet nebulizer, achieving rapid DAH con-
trol, with the disappearance of hemoptysis and a rapid
increase in PaO2 and the PaO2/FiO2 ratio.
Three boluses of 1 g methylprednisolone were adminis-
tered, and 500 mg rituximab was later added to therapy.
The patient's condition improved, with follow-up radio-
graphs and a CT scan showing the resolution of the infil-
trates, after 24 h (Figure 2).Figure 1 Chest X-ray and CT scan. (A) Chest X-ray where bilateral pulmo
scan where mixed basal pulmonary infiltrates and alveolar collapse were obDiscussion
DAH is a rare complication of SLE with high mortality.
The most common age of onset is around 30 years [11,12].
DAH usually occurs in patients with an established diagno-
sis of SLE; however, it can also be the initial manifestation
of this disease [13,14].
The proposed mechanisms for DAH development in-
clude precapillary and alveolar space damage mediated by
immune processes. Three different patterns have been de-
scribed histopathologically: subclinical hemorrhage, capil-
laritis, and diffuse alveolar damage [15-18].
Most cases are associated with slight bleeding without
any sign of vasculitis, interstitial inflammation, or infec-
tion; however, scientific evidence has shown an increase
in the incidence of capillaritis [19,20].
Patients with SLE who present a triad of hemoptysis,
sudden drop in hemoglobin in 24–48 h, and new alveo-
lar or interstitial infiltrates should be highly suspected of
DAH. The incidence of hemoptysis varies, and it is not
present clinically in some cases, confirmed by bronchos-
copy and bronchoalveolar lavage fluid examination that
shows erythrocytes and hemosiderin-laden macrophages.
DAH is associated with other symptoms and signs such
as fever, dyspnea, cough, and pleural effusion. The most
common extrapulmonary manifestation of SLE is renal
involvement, which usually manifests as nephritis class
III or IV. A higher risk of DAH has been found in patients
with active renal disease, especially nephrotic syndrome.
Serological analysis in these patients shows a distinctive
high anti-dsDNA titer, hypocomplementemia, and anemia,
as was the case in our patient. With regard to the radio-
graphic findings, diffuse alveolar infiltrates were evident
from plain radiographs and CT, but did not involve the
lung apices [6,12,19-23].
Bronchoscopy has been recommended in the case of
suspicion of DAH in which clinical presentation is atypical,
as it confirms the diagnosis. In subacute cases, methods
such as the quantitative score of hemosiderin-laden macro-
phages in the BAL fluid sample or increased red blood cell
counts are used [6]. Hemosiderin, a breakdown product ofnary infiltrates were observed. (B) Computed axial tomography (CT)
served. Images were taken at the time of admission (day 1).
Figure 2 Chest radiography and CT scan. (A) Radiography of the chest after treatment with rFVIIa, steroids, and rituximab where the resolution
of pulmonary infiltrates was observed. (B) Chest CT scan where the resolution of infiltrates and alveolar collapse was confirmed (7th day).
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and early stages, as it appears at least 48 h after
bleeding [24,25].
The treatment of DAH is based on high doses of
steroids. This therapeutic approach achieves good results,
especially when administered early. Cyclophosphamide or
plasmapheresis can be added to the treatment when the
response is not satisfactory [26,27].
Mendoza et al. [28] reviewed the treatment of patients
with DAH secondary to SLE, exploring the therapeutic
potential of rituximab (anti-CD20 monoclonal antibody).
Most cases showed significant improvements in clinical
and laboratory parameters, with good tolerance and few
side effects. Thus, patients with severe lupus nephritis
showed improvement in the disease activity with a sig-
nificant reduction (p < 0.05) of proteinuria (from 3.710 to
1.786 g/L, p < 0.05). Patients with severe neurological
involvement had complete symptom remission.
The rFVIIa is a medication approved for the treatment
of hemorrhage in patients with hemophilia A or B who
produce antibodies to FVIII or IX. FVII initiates clot for-
mation by interaction with TF. The FVIIa-TF complex
activates factor X. At high doses (80 to 100 mg/kg),
activated FVII also activates factor X in the absence of
TF, most likely via the activation of factor X bound to
the surface of activated platelets. Factor Xa activates pro-
thrombin to thrombin, which in turn converts fibrinogen
to fibrin [29,30].
It has been proven that rFVIIa has a hemostatic effect
in DAH patients of different etiologies [31-33]. Heslet
et al. [34] published one case series in which they evalu-
ated the use of rFVIIa in six patients with DAH, in
which rFVIIa was instilled into the bronchial system by
bronchoscopy at a dose of 50 μg/kg with good results,
so it was decided to use this dose in our patient. Carrillo
et al. [35] reported the case of a patient with DAH
secondary to SLE who responded well to intravenous
rFVIIa. Grochova et al. [36] reported a case of acute
DAH secondary to stem cell transplantation, confirmed
by bronchoscopy, which successfully responded to the
administration of rFVIIa at a dose of 50 μg/kg in each ofthe intrapulmonary main bronchi by bronchoscopy.
Dabar et al. [37] reported two DAH cases secondary to
acute leukemia and granulomatous vasculitis, respectively,
both successfully treated with intrabronchial rFVIIa ad-
ministered by bronchoscopy. Estella et al. [38] reported
two cases of DAH secondary to SLE, both successfully
treated with the intrabronchial instillation of 90 μg/kg
rVIIa by bronchoscopy. rFVIIa is a glycoprotein of 406
amino acids, has a synthetic G0 plasma activity analogous
to that of FVII, has a molecular weight of 50 kDa, and has
a half-life of 3 h. Its effect is immediate and clinical
hemostasis is observed in 10 min. It was developed in the
1980s for the treatment of bleeding in patients with con-
genital hemophilia with inhibitors and in some cases for
patients with congenital FVII deficiency. Since the 1990s,
the first series published about its use were in non-
hemophiliac patients with severe hemorrhage of different
etiologies [38,39].
The dose of rFVIIa used in different reports is 40–
300 μg/kg. The recommended dose in patients with
microvascular bleeding is 60 to 100 μg/kg bolus, with a
second dose after 20 min if they had not obtained satisfac-
tory hemostatic control. In our work, we administered a
first dose of 100 μg/kg, and due to rebleeding, a second
dose was necessary to obtain appropriate response [40].
In all published cases related to the use of rFVIIa in
DAH, this medication has been administered by an intra-
bronchial or intravenous route. In the case of our patient,
the route of administration was by inhalation using a jet
micronebulizer, obtaining a favorable outcome, which
opens a new opportunity and route of administration for
the use of rFVIIa in DAH. This new approach is sup-
ported on the basis that hemostasis can be achieved by
the interaction of rFVIIa and TF expressed at the alveolar
level when an immune/inflammatory process is taking
place [41].
The mechanism of action of alveolar hemostasis is pri-
marily explained by the TF-dependent pathway, where
alveolar TF is expressed during the inflammatory phase
of DAH. Moreover, the tissue factor pathway inhibitor
(TFPI) inhibits the local activation of factor X to Xa by
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produced by alveolar macrophages can increase up to 20
times. Our observations indicate that the intrapulmonary
administration of FVIIa negates TFPI's anticoagulant
effect [42-44].
Clinical trials within the approved indications revealed
that thrombotic events of possible or probable relation-
ship to rFVII occurred in 0.28% of bleeding episodes
treated, with the incidence within hemophilia patients
with inhibitors to be 0.20%, and in acquired hemophilia
an incidence of 4% [45]. Patients with disseminated
intravascular coagulation (DIC), advanced atheroscler-
otic disease, crush injury, septicemia, or concomitant
treatment with activated or nonactivated prothrombin
complex concentrates (aPCCs/PCCs) have an increased
risk of developing thrombotic events.
Two meta-analyses of these pooled data indicate an
increased risk of thrombotic events (10.0% in patients
treated with rFVIIa versus 7.5% in placebo-treated pa-
tients). Arterial thromboembolic adverse events includ-
ing myocardial infarction, myocardial ischemia, cerebral
infarction, and cerebral ischemia were statistically signi-
ficantly increased with the use of rFVIIa compared to
placebo (5.3% to 5.6% in subjects treated with rFVIIa
versus 2.8% to 3.0% in placebo-treated patients). Other
arterial thromboembolic events (such as retinal artery
embolism, renal artery thrombosis, arterial thrombosis
of limb, bowel infarction, and intestinal infarction) have
also been reported [45-49].Conclusion
The DAH in SLE is a catastrophic complication and
is associated with high morbidity and mortality. The
use of rFVIIa by inhalation with a jet nebulizer is an op-
tion for the treatment of this condition, and it should
always be given as a supplement to the standard treatment
(methylprednisolone boluses).Consent
The patient has given consent for the publication of
accompanying documents. The authors are available for
any clarification. The study was approved by the ethics
committee of the Hospital Medica Sur which is governed
by the Declaration of Helsinki.
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